GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » Shiller PE Ratio

Arrowhead Pharmaceuticals (STU:HDP1) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Shiller PE Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arrowhead Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arrowhead Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Shiller PE Ratio falls into.



Arrowhead Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arrowhead Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.938/131.7762*131.7762
=-0.938

Current CPI (Mar. 2024) = 131.7762.

Arrowhead Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.162 100.560 -0.212
201409 -0.341 100.428 -0.447
201412 -0.333 99.070 -0.443
201503 -0.471 99.621 -0.623
201506 -0.241 100.684 -0.315
201509 -0.365 100.392 -0.479
201512 -0.294 99.792 -0.388
201603 -0.314 100.470 -0.412
201606 -0.285 101.688 -0.369
201609 -0.303 101.861 -0.392
201612 -0.161 101.863 -0.208
201703 -0.075 102.862 -0.096
201706 -0.062 103.349 -0.079
201709 -0.126 104.136 -0.159
201712 -0.152 104.011 -0.193
201803 -0.146 105.290 -0.183
201806 -0.154 106.317 -0.191
201809 -0.103 106.507 -0.127
201812 0.114 105.998 0.142
201903 0.212 107.251 0.260
201906 0.186 108.070 0.227
201909 0.100 108.329 0.122
201912 -0.027 108.420 -0.033
202003 -0.181 108.902 -0.219
202006 -0.115 108.767 -0.139
202009 -0.408 109.815 -0.490
202012 -0.164 109.897 -0.197
202103 -0.218 111.754 -0.257
202106 -0.241 114.631 -0.277
202109 -0.519 115.734 -0.591
202112 -0.531 117.630 -0.595
202203 0.372 121.301 0.404
202206 -0.643 125.017 -0.678
202209 -0.818 125.227 -0.861
202212 -0.368 125.222 -0.387
202303 0.420 127.348 0.435
202306 -0.886 128.729 -0.907
202309 -0.956 129.860 -0.970
202312 -1.137 129.419 -1.158
202403 -0.938 131.776 -0.938

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arrowhead Pharmaceuticals  (STU:HDP1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arrowhead Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines